All In Biotech

NDA 021269 · Viatris

Cardura Xl

Doxazosin Mesylate · Oral

Last checked: Nov 20, 2026Latest source record: Jun 22, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Feb 22, 2005

Approved uses

1

Original approval plus efficacy supplements

Registered trials

59

6 Phase 3, 0 recruiting

FAERS reports

15,500

12,187 serious, 1,476 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 15, 2023.

CARDURA ® XL is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). CARDURA XL is not indicated for the treatment of hypertension. CARDURA XL is an alpha 1 adrenergic antagonist indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia. ( 1 ) CARDURA XL is not indicated for the treatment of hypertension. ( 1 )

Mechanism: The symptoms associated with benign prostatic hyperplasia (BPH), such as urinary frequency, nocturia, weak stream, hesitancy, and incomplete emptying are related to two components, anatomical (static) and functional (dynamic). The static component is related to an increase in prostate size caused, in part, by a proliferation of smooth muscle cells in the prostatic stroma. However, the severity of BPH symptoms and the degree of urethral obstruction do not correlate well with the size of the prostate. The dynamic component of BPH is associated with an increase in smooth muscle tone in the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • CARDURA XL · DOXAZOSIN MESYLATE EQ 8MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • CARDURA XL · DOXAZOSIN MESYLATE EQ 4MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Doxazosin" as an intervention, any sponsor and status, largest first.

All 59 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea882
  • fatigue762
  • dizziness744
  • diarrhoea726
  • drug ineffective714
  • asthenia695
  • nausea628
  • hypotension623
  • headache523
  • hypertension522
  • fall487
  • pain469

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004595
2005514
2006575
2007738
2008652
2009708
2010878
20111,142
2012999
2013471
2014598
2015738
2016694
2017572
2018758
2019694
2020619
2021610
2022775
2023584
2024655
2025540
2026391

Recalls

2 FDA enforcement reports for this application.

  • Dec 23, 2024 · Class II · Terminated

    Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.

  • Dec 23, 2024 · Class II · Terminated

    Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cardura XL (Doxazosin Mesylate)

2024 spending

$821K

Beneficiaries

698

2,157 claims

Per beneficiary

$1,177

$6.71 per unit

View as table
YearSpending
2020$780,192
2021$820,308
2022$703,081
2023$804,454
2024$821,349

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 507 on PubMed

Sponsor: Viatris

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.